TP53
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
Li-Fraumeni Syndrome, breast cancer, osteosarcoma, soft tissue sarcoma, some leukemias and lymphomas, papilloma of choroid plexus, brain cancer, adrenal cortical tumors, colon cancer, ovarian, and esophageal cancers, lung cancer, myelodysplastic neoplasm, Chronic Lymphocytic Leukemia
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. TP53 mutations are potential prognostic and predictive markers, as well as targets for pharmacological intervention.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
YES
TAT
1 Day
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
